Overview
Implantica AG is a pioneering medical technology company based in Liechtenstein, primarily engaged in the development and commercialization of innovative products designed to improve the health outcomes and quality of life for patients worldwide. The company operates principally in the field of gastroenterology and urology, with its flagship product, RefluxStop™, a revolutionary device that addresses gastroesophageal reflux disease (GERD) more effectively than traditional surgical methods, with fewer side effects and better patient comfort. Implantica's portfolio highlights its commitment to leveraging advanced technology, such as eHealth and artificial intelligence, to transform traditional medical treatments, ensuring the company remains at the forefront of healthcare innovation. This strategic focus on technologically advanced medical devices places Implantica as a leader in the medical implant industry.
Basic Stats
The share price of Implantica AG - Depositary Receipt (Common Stock) as of 1 September 2025 is 62,10 kr / share. This is a decrease of -11.16% from the prior week. The market cap (or net worth) of Implantica AG - Depositary Receipt (Common Stock) as of 1 September 2025 is 17 586,07 kr MM.
The Factor Analysis chart (below right) shows a view of Implantica AG - Depositary Receipt (Common Stock) from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 17,586.07 MM |
| EV | |
| Shares Out. | 283.19 MM |
| Earnings Date | |
| EPS (TTM) | -0.08 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | |
| Short Shares Avail. | |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | 36.63 % |
| Volatility (1 yr) | 0.62 |
| Beta | 1.10 |
| Sharpe Ratio (1 yr) | 0.53 |
| Sortino Ratio (1 yr) | 1.06 |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | -0.19 |
| ROE | -0.19 |
| ROIC | -0.23 |
| CROIC | -0.56 |
| OCROIC | -0.20 |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | 80.69 /100 |
| Profitability | 7.19 /100 |
| Quality Score | 21.55 /100 |
| Value Score | |
| Momentum Score | 64.92 /100 |
| Stability (Low Vol) Score | |
| Analyst Sentiment | 24.78 /100 |
| Fund Sentiment | |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE | 5.00 /9 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Implantica AG - Depositary Receipt (Common Stock). An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2023-08-28 | PARETO SECURITIES AS | Buy | Buy | Maintains |
| 2023-05-14 | PARETO SECURITIES AS | Buy | Buy | Maintains |
| 2023-02-20 | PARETO SECURITIES AS | Buy | Buy | Maintains |
| 2023-11-27 | PARETO SECURITIES AS | Buy | Buy | Maintains |
| 2023-08-29 | PARETO SECURITIES AS | Buy | Buy | Maintains |
| 2023-05-15 | PARETO SECURITIES AS | Buy | Buy | Maintains |
| 2024-07-02 | PARETO SECURITIES AS | Buy | Buy | Maintains |
| 2023-11-26 | PARETO SECURITIES AS | Buy | Buy | Maintains |
| 2024-11-18 | PARETO SECURITIES AS | Buy | Buy | Maintains |
